Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Lymphoblastic LeukaemiaAcute Myeloid LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupHigh riskMDS with elevated blasts -2ICD10C91.0-C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningSequenceAMLSG 31-19/HOVON 501ChemotherapyChemo-substanceAzacitidineCytarabineDaunorubicinGlasdegibLenalidomideMelphalanVenetoclaxChemo-substanceAzacitidineCytarabineDaunorubicinGlasdegibLenalidomideMelphalanVenetoclaxChemo-substanceAzacitidineCytarabineDaunorubicinGlasdegibLenalidomideMelphalanVenetoclaxChemo-substanceAzacitidineCytarabineDaunorubicinGlasdegibLenalidomideMelphalanVenetoclaxNo. Substances123 RadiotherapySupportive therapySupportive substanceAllopurinolAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFilgrastimFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPegfilgrastimPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAllopurinolAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFilgrastimFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPegfilgrastimPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAllopurinolAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFilgrastimFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPegfilgrastimPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAllopurinolAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFilgrastimFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPegfilgrastimPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirNo. Substances1235610111216Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityKonditionierung, intensitäts- oder dosisreduziert (RIC)Konditionierung, myeloablativ (MAC)Konditionierung, nicht-myeloablativ (NMA)Low doseStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseallogene StammzelltransplantationConsolidationInductionTherapy intentioncurativecurative or palliativepalliativeRisksAnemia Hb below 8g/dlAstheniaBleedingCardiotoxicityColitisDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityHyperbilirubinemiaInfectionsNeurotoxicityNeutropeniaPainPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorAnand S Beelen DWCiurea SOCortes JECraddock CDöhner HEstey EKornblit BLübbert MMarks RPlatzbecker URambaldi ASchroeder TShimoni ASolomon SRStratmann JDiseaseAML, 40-65 Jahre, ECOG 0-2, < 5% BlastenAML, MDS, CML, NHL, ungeeignet für konventionelle intensive KonditionierungAML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML/ALL/MDS, allogene SCTAML/MDS, 18-65 Jahre, < 5% BlastenAML/MDS, 18-70 Jahre, AML in kompletter hämatologischer Remission (unter 5% Blasten) oder MDS (unter 20% Blasten), HCT-CI Score über 2AML/MDS, ALL, allogene StammzelltransplantationAML/MDS, ALL, NHL, Stammzelltransplantation mit NabelschnurblutAML/MDS, allogene StammzelltransplantationAML/MDS, ungeeignet für konventionelle intensive KonditionierungAML/MDS, unter 55 JahreAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2de-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDrohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)Neu diagnostizierte AML oder MDS mit Blastenüberschuss-2, ECOG 0-2OriginAlbert-Ludwigs University Medical Center, Freiburg, GermanyCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WashingtonDepartment of Haematology and Oncology, Albert-Ludwigs University Medical Center, FreiburgDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyDivision of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North CarolinaHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, ItalyHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GeorgiaThe Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, IsraelThe University of Texas M. D. Anderson Cancer Center, Houston, USAUlm University Hospital, Germany, AMLSG 31-19/HOVON 501University of Birmingham, Birmingham, United KingdomUniversity of Texas, MD Anderson Cancer Center, Houston, USAUniversity of Texas MD Anderson Cancer Center, Houston, USAWest German Cancer Centre, University of Duisburg-Essen, Essen, GermanyProtokolle in Überarbeitung 21 protocols foundAzacitidine 100, Acute Myeloid Leukemia, and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation (PID2302 V1.0)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation, Variant 1 (PID2320 V1.0)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome following Allogeneic Stem Cell Transplantation (PID827 V1.2)Azacitidine 75, Acute Myeloid Leukemia, and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation (PID2327 V1.0)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674 V1.0)Fludarabine 30 / Carmustine 150 / Melphalan 110, Allogeneic Stem Cell Transplantation, RIC (PID880 V1.0)Fludarabine 30 / Carmustine 200 / Melphalan 140, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID1705 V1.0)Fludarabine 30 / Melphalan 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID3225 V1.0)Fludarabine 30 / TBI 12, Allogeneic Stem Cell Transplantation, MAC (PID3219 V1.0)Fludarabine 30 / TBI 2, Allogeneic Stem Cell Transplantation, NMA (PID3222 V1.0)Fludarabine 30 / Treosulfan 10, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, MAC (PID1706 V1.0)Fludarabine 40 / Busulfan 0.8 / Anti-thymocyte Globulin (Rabbit) (0.5/2.0/2.5), Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation, MAC (PID885 V1.0)Fludarabine 40 / Busulfan 3.2 / Anti-thymocyte Globulin (Rabbit) 10, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, MAC (PID881 V1.0)Melphalan 140 / Thiotepa 10 / Fludarabine 40, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID1738 V1.0)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735 V1.1)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction II, over 60 years of age (PID3142 V1.0)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, consolidation, over 60 years of age (PID3144 V1.0)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1500 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Consolidation, under 60 years of age (PID3143 V1.0)Study-AMLSG 31-19/HOVON 501 - Daunorubicin 60 / Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction II, under 60 years of age (PID3141 V1.0)Study-AMLSG 31-19/HOVON 501 - Daunorubicin 60 / Cytarabine 200 / Venetoclax (100/200/400), Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction I (PID3140 V1.0)Thiotepa 5 / Fludarabine 40 / TBI 13.5, Allogeneic Stem Cell Transplantation, MAC (PID3224 V1.0)
